Gufic Biosciences Limited · NSE:GUFICBIO
Gufic Biosciences — Q2 FY2021-22 Earnings Presentation
25 slides from Gufic Biosciences's earnings presentation, Nov 8, 2021
Slide 1: Intimation of Earnings Conference Call
105/LG/SE/NOV/2021/GBSL November 08, 2021 To, To, Listing Department, Listing Department, BSE Limited, National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Bandra (E), Mumbai – 400 051 Mumbai – 400 001 Security Code : GUFICBIO Securi
Slide 2: Dial-in Information and Company Secretary Sign-off
Internatio Hong Kong : +852 30186877 nal Toll Japan : +81 345899421 Singapore : +65 31575746 South Africa : +27 110623033 UK : +44 2034785524 USA : +1 3233868721 Please note that the schedule of the above-mentioned meeting is subject to change and the change may occur due to exigencies on the part o
Slide 3: Delivering Care & Cure: Gufic moving in the right direction
Delivering Care & Cure Gufic moving in the right direction
Slide 4: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties including impact of Covid-19 and other factors that
Slide 5: Q2 FY 2021-22: Business Overview
Q2 FY 2021-22 : Business Overview As per IQVIA Sept 2021 MAT dataset, we are the 4th fastest growing company amongst the top 100 companies of Indian Pharma Market The Clinical Trial of Immunocin Alpha (Thymosin Alpha-1) in COVID-19 has been completed and presentation is made to DCGI. Approval from D
Slide 6: Q2 FY 2021-22: Business Overview
Q2 FY 2021-22 : Business Overview The API Research & Development at Navsari has made noteworthy progress in development of molecules in therapeutic categories such as: Antifungal, Anticoagulant, Tetracycline-Antibiotics, Progestin, Beta-3-adrenegic agonists, Antidiabetic, Cyclopeptides & Hormones. T
Slide 7: Q2 FY 2021-22: Business Overview
Q2 FY 2021-22 : Business Overview Our application for IS -6 (a novel Anti-Fungal agent) is done to DCGI. We are awaiting for DCGI comments to initiate the required studies We are on-track with the development of 3 new biological peptides in the field of Gynaecology. The products are expected to be c
Slide 8: Moving in the right direction… to create healthy lives!
Moving in the right direction… to create healthy lives ! Gufic is research based pharmaceutical company, recognized for its innovative, high-quality Pharmaceuticals, Nutraceuticals, Natural / Herbal products. Gufic is the 4th fastest growing company among the top 100 pharma companies in India Gufic
Slide 9: Our broad Business Structure
Our broad Business Structure Domestic Contract Bulk Drug International Business manufacturing Business Business Business 8 well defined Strategic One of the largest facility Exclusive facility for API. Operation spread across Business Units for Lyophilization Specialization in more than 20 countries
Slide 10: Certifications and Manufacturing Capacity
Gufic Biosciences Ltd Unit-I Unit-II Gufic - Vadodara Gufic - Belgaum Botulinum Toxin facility Lyophilized/powder Lyophilized injectables facility Sanitary Napkins facility Natural products facility injectables facility Natural Products API facility Capability to manufacture (Topical/Liquid) Liposom
Slide 11: Upcoming World Class Manufacturing Infrastructure at Indore
Upcoming World Class Manufacturing Infrastructure at Indore Gufic Biosciences Ltd Unit-III Unit-IV Dedicated facility for Lyophilized injectables facility Penem Capability to cater regulated Carbapenems (Lyophilized / Dry markets such as US & EU Powder Inj / Oral Solids / Dual Chamber Bags • Lyophil
Slide 12: Gufic Biosciences Manufacturing Facility
Gufic Biosciences Manufacturing Facility Gufic Biosciences Ltd is a WHO GMP, EU GMP, ANVISA Brazil, Russian GMP, Health Canada, Ukraine GMP, Australia TGA, Colombia INVIMA, Uganda NDA and SAHPRA South Africa approved company with a total capacity of 30 million lyophilized vials per annum. Product po
Slide 13: Botulinum Toxin Facility
Botulinum Toxin Facility Gufic has built a state - of - the - art manufacturing facility for Botulinum Toxin in Navsari, India. Gufic has partnered with Prime Bio, USA for manufacturing Botulinum ToxinAPI and formulation. Gufic is equipped with all the necessary analytical testing procedures for safe
Slide 14: Expanding our Geographical Reach
Expanding our Geographical Reach PRESENCE IN STRATEGIC LOCATIONS ACROSS THE GLOBE Our operations is spread pan- India and 20+ countries worldwide 130+ Products registered globally (in 15+ countries) 150+ products in pipeline for registration (in 30+ countries) • CANADA • COSTA RICA • PANAMA • COLUMB
Slide 15: Consolidating our India Business
Consolidating our India Business India Business Pan - India Presence in multiple Therapy Areas Natural & Ortho-Gynaec Dermo-Cosmetic Critical Care Infertility Mass Specialty Nutraceutical Products Products Products STELLAR Aesthaderm Field Force: > 180 Field Force: > 300 Field Force: > 60 Field Forc
Slide 16: Gufic - Wide-spread Therapy Presence
Gufic - Wide-spread Therapy Presence Product offerings in Multiple therapy areas across the pharmaceutical market Anti-Infectives Anti Fungal Blood Related Gastrointestinal Women Health Hormones Respiratory Osteoporosis Arthritis Dermo-Cosmetics Pain Hepatoprotectives Immunity Infertility Management
Slide 17: Our strong Partnership and licensing deals
Gufic - Our strong Partnership and licensing deals Therapy area: Toxins - Strain transfer, Tech-transfer, formulation Bo development and manufacturing at Gufic Therapy area: Infertility Tech-transfer and Clinical development(Phase-III) of the product at Gufic Therapy area: Dermo-cosmetics Technical
Slide 18: Expanding Our credibility in the CMO Business
GUFIC - Expanding Our credibility In the CMO Business Our Esteemed Partners We offer CMO services for India and Global markets: Reliable CMO service for quality products over a decade 70 + Companies 150 + Products across multiple therapy areas One of the Largest supplier of formulations-Doxycycline,
Slide 19: Extensive Sales, Distribution & IT Infrastructure in India
Extensive Sales, Distribution & IT Infrastructure in India 2 Central Warehouses 23 C&F Agents 1200 Plus Stockists 1000 + Field Force Pan India Presence with a field force > 1000+ Two central ware house located in North-Delhi & West-Bhiwandi 23 Carrying & Forwarding agents across India 1200 Stockists
Slide 20: Our robust R&D and Clinical team to augment growth
Our robust R & D and Clinical team to augment growth R&D Clinical Team State-of-the-art R&D Facility Strong Clinical team comprising of located in Navsari, Gujarat Medical with expertise in Regulatory Formulation Development Product Development Technology-Transfer Capabilities to take Synthetic and
Slide 21: Building our API Capabilities
Building our API Capabilities Special facility dedicated to API Focused on developing non-infringing, novel, cost-effective and scalable chemical process for APIs, Peptides and Cyclopeptides The categories of API’s manufactured are antifungals, antibacterial, anesthetics and intermediates for antifu
Slide 22: Our Strategic Growth Levers
Gufic - Our Strategic Growth Levers India Business Consolidation of the Critical Care / Infertility business Entry into new therapy areas Dermatology - Aesthaderm Strategic focus on Healthcare division with entry into Ortho-Gynecology products through a new division - Stellar Build a robust pipeline
Slide 23: Financial Highlights – Q2 FY 2021-22
Financial Highlights – Q2 FY 2021-22 Amt in Lacs Half Yearly Quarterly Particulars HYD Sep-21 HYD Sep-20 Growth Q2 FY21 Q2 FY20 Growth Net Sales 44,490 18,921 135% 19,414 12,842 51% EBITDA 8,301 3,580 132% 3,613 3,167 14% Margin% 18.7% 18.9% Profit Before Tax 7,193 2,021 256% 3,039 2,301 32% Profit
Slide 24: Corporate Citizenship
Corporate Citizenship COMMUNITY HEALTHCARE, EDUCATION, KNOWLEDGE SOCIAL CARE AND Gufic’s strong focus on SANITATION AND HYGIENE AND RESEARCH CONCERN promoting and supporting the cause of child education Assist people living in areas Assist underprivileged Generate employment has been recognized by S
Slide 25: Thank You
Thank You For any queries, please contact Avik Das (Investor Relations) avik.das@guficbio.com Ami Shah (Company Secretary and Compliance Officer) mgr_legal@guficbio.com Tel: +91-22-67261000
Gufic Biosciences — Q2 FY2021-22 Earnings Presentation on 6ix